New England Journal of Medicine (NEJM) recently published detailed, 10-year follow-up data from a 2009 Moers et al. clinical study featuring LifePort Kidney Transporter. The 2009 study, a multicenter, randomized, paired-kidney clinical trial following 672 recipients, was the first study to showcase the benefits of hypothermic machine perfusion (HMP) for kidney preservation in transplantation as used in ORS’ LifePort Kidney Transporter.

Here we highlight the progression of findings, as well as the new 10-year follow-up data:

Moers et al 2009

• HMP with LifePort reduced DGF
• 1-year graft survival significantly better with LifePort vs. SCS

Moers et al 2012

• Significantly better 3-year graft survival with LifePort – especially in ECD kidneys

Moers et al 2025 (post-hoc analysis)

• LifePort reduced the risk of graft failure at 10 years post transplant vs SCS
• Adjusted hazard ratio reached statistical significance
• Echoing Moers et al 2012, better graft survival with LifePort vs. SCS, including those from medically complex donors

The data is evident: overall graft survival benefit with LifePort Kidney Transporter remains after 10 years.

Read the full study: nejm.org/doi/full/10.1056/NEJMc2406608